Novartis awarded 55 mln usd vaccine development contract from US govt |
|
|
|
Published
:
Wed, 17 Jan 2007 18:36
|
BASEL (AFX) - Novartis AG said it has received a contract from the US health department worth approximately 55 mln usd to further develop a novel antigen technology that could extend vaccine supplies in a pandemic outbreak.The contract supports the company's efforts to develop and manufacture its MF59 adjuvant in the US, the Basel-based drug maker said.An adjuvant is a substance added to a vaccine to enhance the body's immune response to the vaccine's active constituent.afx.zurich@afxnews.comat/cmlCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Chiron gets bird flu vaccine order from British government 